Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwNHL 2015

03 October 2015

iwNHL 2015

03 October 2015
Therapeutic opportunities for lenalidomide in non-Hodgkin lymphoma 3:12
Therapeutic opportunities for lenalidomide in non-Hodgkin lymphoma
Nathan Fowler • 3 Oct 2015
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies 5:45
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies
Owen O'Connor • 3 Oct 2015
Approaches to overcome side effects of idelalisib for follicular lymphoma 5:08
Approaches to overcome side effects of idelalisib for follicular lymphoma
John Gribben • 3 Oct 2015
Duvelisib, dual inhibitor of PI3K delta and PI3K gamma, for indolent non-Hodgkin lymphoma 4:14
Duvelisib, dual inhibitor of PI3K delta and PI3K gamma, for indolent non-Hodgkin lymphoma
Ian Flinn • 3 Oct 2015
Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma 3:36
Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma
John Kuruvilla • 3 Oct 2015
iwNHL 2015 roundtable: Immune checkpoint blockade for non-Hodgkin lymphoma 13:10
iwNHL 2015 roundtable: Immune checkpoint blockade for non-Hodgkin lymphoma
Anas Younes et al. • 3 Oct 2015
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma 16:39
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
Andrew Zelenetz et al. • 3 Oct 2015
Monoclonal antibody therapies for cutaneous T-cell lymphoma 2:22
Monoclonal antibody therapies for cutaneous T-cell lymphoma
Pier L. Zinzani • 3 Oct 2015
Determining effective combinations of immune checkpoint inhibitors for lymphoma 3:30
Determining effective combinations of immune checkpoint inhibitors for lymphoma
Stephen Ansell • 3 Oct 2015
Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma 4:42
Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma
Thomas Kipps • 3 Oct 2015
iwNHL 2015 roundtable: Day 2 highlights – PI3K inhibitors 3:07
iwNHL 2015 roundtable: Day 2 highlights – PI3K inhibitors
John Gribben et al. • 3 Oct 2015
iwNHL 2015 roundtable: Day 2 highlights – ibrutinib for diffuse large B-cell lymphoma 7:44
iwNHL 2015 roundtable: Day 2 highlights – ibrutinib for diffuse large B-cell lymphoma
John Gribben et al. • 3 Oct 2015
iwNHL 2015 roundtable: Day 2 highlights – lenalidomide and ibrutinib for DLBCL 2:33
iwNHL 2015 roundtable: Day 2 highlights – lenalidomide and ibrutinib for DLBCL
John Gribben et al. • 3 Oct 2015
iwNHL 2015 roundtable: Day 2 highlights – bortezomib, proteasome inhibitor, for B-cell lymphoma 3:12
iwNHL 2015 roundtable: Day 2 highlights – bortezomib, proteasome inhibitor, for B-cell lymphoma
John Gribben et al. • 3 Oct 2015
iwNHL 2015 roundtable: Day 2 highlights – CAR T-cell therapy for non-Hodgkin lymphoma 3:29
iwNHL 2015 roundtable: Day 2 highlights – CAR T-cell therapy for non-Hodgkin lymphoma
John Gribben et al. • 3 Oct 2015
iwNHL 2015 roundtable: Biology of diffuse large B-cell lymphoma 8:41
iwNHL 2015 roundtable: Biology of diffuse large B-cell lymphoma
Catherine Bollard et al. • 3 Oct 2015
The content of VJHemOnc is intended for healthcare professionals